Discontinued Product

DFB (Cat. No. 1625) has been withdrawn from sale for commercial reasons.
Description: Positive allosteric modulator of mGlu5 receptors
Alternative Names: 3,3'-Difluorobenzaldazine
Chemical Name: [(3-Fluorophenyl)methylene]hydrazone-3-fluorobenzaldehyde
Purity: ≥99% (HPLC)
Citations (1)
Literature (5)

Biological Activity for DFB

DFB is a novel allosteric potentiator of the metabotropic glutamate receptor mGlu5. Devoid of agonist activity itself, but potentiates (3 - 6-fold) the action of agonists at mGlu5 without any effect at other mGlu subtypes (EC50 for potentiation = 2 - 5.3 μM).

Technical Data for DFB

M. Wt 244.24
Formula C14H10F2N2
Storage Store at +4°C
Purity ≥99% (HPLC)
CAS Number 15332-10-2
PubChem ID 52942441
Smiles FC1=CC(=CC=C1)\C=N\N=C\C1=CC=CC(F)=C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

References for DFB

References are publications that support the biological activity of the product.

O'Brien et al (2003) A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5. Mol.Pharmacol. 64 731 PMID: 12920211

Zhang et al (2005) Allosteric potentiators of metabotropic glutamate receptor subtype 5 have differential effects on different signaling pathways in cortical astrocytes. J.Pharmacol.Exp.Ther. 315 1212 PMID: 16135701

Williams et al (2002) DFB, an allosteric potentiator of mGluR5 4th International Meeting on Metabotropic Glutamat

View Related Products by Product Action

View all Glutamate (Metabotropic) Group I Receptor Modulators

Keywords: DFB, DFB supplier, Allosteric, potentiators, mGlu5, mGluR5, Group, I, Receptors, Glutamate, Metabotropic, PAM, 3,3'-Difluorobenzaldazine, (Metabotropic), 1625, Tocris Bioscience

1 Citation for DFB

Citations are publications that use Tocris products. Selected citations for DFB include:

Chen et al (2011) mGluR5 positive modulators both potentiate activation and restore inhibition in NMDA receptors by PKC dependent pathway. J Biomed Sci 18 19 PMID: 21342491

Reviews for DFB

There are currently no reviews for this product. Be the first to review DFB and earn rewards!

Have you used DFB?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Metabotropic Glutamate Receptors Scientific Review

Metabotropic Glutamate Receptors Scientific Review

Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.

Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Huntington's Disease Poster

Huntington's Disease Poster

Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.